On May 24,2018 Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that its CEO, Walter Klemp, was asked to address the 2018 BioForum Conference in Łódź, Poland (Press release, Moleculin, MAY 24, 2018, View Source [SID1234526880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Moleculin Chairman and CEO was asked to give a lecture on Polish-American Innovation Bridge: Bringing validated innovations from USA to Poland. Now, in its 17th edition, BioForum 2018 has become one of the biggest partnering conferences in Central Europe, providing the world’s most innovative leaders across the life science sector to network and do business with one another.

"We are honored that Moleculin’s innovative approach to global collaboration is being used as an example of cutting edge development," commented Walter Klemp, Moleculin’s Chairman and CEO. "Our partnerships in Poland have already facilitated more rapid development of our drug pipeline. We look forward to continuing to leverage the strengths of both the US and Poland to create faster, more cost-effective outcomes."